The combination of silymarin and pegylated interferon alpha2b attenuates the progression of liver fibrosis in prior nonresponders and relapsers with chronic hepatitis C infection – the PROFI C trial

2008 ◽  
Vol 46 (01) ◽  
Author(s):  
M Ocker ◽  
D Neureier ◽  
D Schuppan ◽  
C Herold
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Liver Fibrosis ◽  
Chronic Hepatitis C ◽  
Pegylated Interferon ◽  
Hepatitis C Infection

Decrease in liver fibrosis after achieving SVR in patients with chronic Hepatitis C infection

2015 ◽  
Vol 53 (05) ◽  
Author(s):  
K Kozbial ◽  
S Beinhardt ◽  
C Freissmuth ◽  
A Stättermayer ◽  
R Stern ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Liver Fibrosis ◽  
Chronic Hepatitis C ◽  
Hepatitis C Infection

scholarly journals High prevalence of autoantibodies to C-reactive protein in patients with chronic hepatitis C infection: association with liver fibrosis and portal inflammation

2012 ◽  
Vol 73 (4) ◽  
pp. 382-388 ◽  
Author(s):  
Christopher Sjöwall ◽  
Kristina Cardell ◽  
Elisabeth A. Boström ◽  
Maria I. Bokarewa ◽  
Helena Enocsson ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Liver Fibrosis ◽  
Chronic Hepatitis C ◽  
C Reactive Protein ◽  
Hepatitis C Infection ◽  
Reactive Protein ◽  
High Prevalence

Equally Poor Outcomes to Pegylated Interferon-based Therapy in African Americans and Hispanics With Chronic Hepatitis C Infection

2010 ◽  
Vol 44 (2) ◽  
pp. 140-145 ◽  
Author(s):  
Sanjaya K. Satapathy ◽  
Chandra Sekhar Lingisetty ◽  
Shawnette Proper ◽  
Shobhana Chaudhari ◽  
Susan Williams
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
African Americans ◽  
Chronic Hepatitis C ◽  
Pegylated Interferon ◽  
Hepatitis C Infection ◽  
Poor Outcomes
Sign in / Sign up

Export Citation Format

Share Document